Approximately 40% of patients with hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer have a mutation in the PIK3CA gene, which can result in endocrine therapy resistance and poor prognosis. Oncology physicians Virginia Kaklamani, MD, DSc, and Joanne Mortimer, MD, discuss how to incorporate therapies that target PIK3CA mutations to enhance treatment outcomes in this patient population. Key information in this discussion includes appropriate candidates and methods for biomarker testing (including PIK3CA mutations), clinical trial data supporting the use of PIK3CA targeted therapies in the first-line and second-line metastatic settings, and important clinical considerations for treatment selection. Drs. Kaklamani and Mortimer also discuss toxicity management, including hyperglycemia monitoring and treatment, and the importance of good communication and collaboration among the interprofessional, multidisciplinary care team. The 0.75-hour activity promotes critical thinking and application of key concepts to patient cases, enabling participants to advance the care they provide to patients with HR+/HER2- metastatic breast cancer.
This content is also available as a podcast: You may listen here.
Course Credit:
0.75 ACPE Contact Hours
0.75 AMA PRA Category 1 CreditsTM
0.75 ANCC Contact Hours
0.75 CA-BRN Contact Hours
0.75 Pharmacology Hours
Dates:
Opens: 2026-01-28
Closes: 2027-01-28
Target Audience:
This activity is intended for physicians, nurses, pharmacists, PAs, and NPs.
This activity is supported by an educational grant from AstraZeneca.
Accreditation
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 0.75 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.
Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.75 ANCC contact hours, including 0.75 pharmacology hours.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
Additional Content Planners
Rachel Feaster, PharmD, BCOP (Medical Writer)No significant relationships to disclose.
Donald Gardenier, DNP (Nurse Reviewer)
No significant relationships to disclose.
Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.
All of the financial relationships listed for these individuals have been mitigated.
-
Virginia Kaklamani, MD
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology
Leader, Breast Oncology Program
UT Health San Antonio, MD Anderson Cancer Center
San Antonio, Texas -
Joanne Mortimer, MD
Vice Chair, Medical Oncology
Professor, Division of Medical Oncology & Experimental Therapeutics
Associate Director for Education and Training
Baum Family Professor of Women's Cancers
City of Hope Comprehensive Cancer Center
Duarte, California
Presenting Faculty
Downloads
Learning Objectives
- Identify appropriate candidates for PIK3CA mutation testing in patients with HR+/HER2- recurrent unresectable or metastatic breast cancer.
- Interpret PIK3CA test results accurately to ensure appropriate use of PI3K and AKT1 inhibitors.
- Select appropriate first- and subsequent-line PIK3CA-targeted therapies based on patient characteristics, previous therapies, and current and emerging evidence.
- Develop an interprofessional, multidisciplinary-focused hyperglycemia monitoring and management plan for patients receiving PI3K and AKT1 inhibitors.
Faculty Disclosures
Virginia Kaklamani, MD
Advisory Board: AstraZeneca, Daiichi, Genentech, Lilly, Menarini, Novartis, Pfizer
Joanne Mortimer, MD
Consultant: AstraZeneca, Bayer, GE Healthcare